Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma

Abstract Background Metastatic urothelial carcinoma (mUC) has a poor prognosis, despite recent therapeutic advancements. Prostaglandin Reductase 1 (PTGR1) is essential for activating acylfulvens, a promising class of drugs for treating a subset of urothelial carcinoma (UC) patients. The efficacy of...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Dag Rune Stormoen, Signe Lehn, Kent W. Mouw, Zoltan Szallasi, Linea Cecilie Melchior, Line Hammer Dohn, Judit Börcsok, Maria Rossing, Birgitte Grønkaer Toft, Helle Pappot
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2024-11-01
Serie:	Scientific Reports
Soggetti:	Bladder cancer Urothelial cancer Biomarker Validation study DNA repair deficiency PTGR1
Accesso online:	https://doi.org/10.1038/s41598-024-79334-x
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!